Table 2.

Summary of PBMC donor characteristics and CTL response(s)a

DonorHLAAge (yr)CD4 count (106)/literRNA copies/μlDate of HIV infectionHIV stageCTL response(s)
H07A2342601 × 105 4/1992II1/3 (VLE)
H08A250200<4002/1984II0/3
H09 A2413801.3 × 105 1985II0/3
H10A2343308.2 × 103 1985IV C17/7b
H11A2503202 × 104 1989IV C10/3
H17 A2447001.1 × 104 2/1996II0/3
H18 A2476101.2 × 105 1985II0/3
H19A235901.3 × 105 12/1993IV C12/7 (PLT, VIY)
H21A247440<4001986II2/7 (SLY, KLT)
H24A248300  5801988II1/7 (SLY)
H27A2484405.3 × 103 1/1991II3/7 (SLY, VIY, ILK)
H28A241601.3 × 105 1994IV C0/7
H30A265250<4005/1997IV C0/7
H33A2355101.5 × 103 2/1997II3/7 (SLY, KLT, AFH)
H12Not A237350<4001995III0/3
H16Not A244300<4009/1997II0/3
H22Not A232520<4009/1996IV C10/1
HC1A246 00/7
HC2A237 00/7
  • a CTL response(s) is given as the number of epitopes for which specific CTL activity could be generated per the number of epitopes tested (first three amino acids of the epitope(s) for which a response was seen). Date of HIV infection is given as year or month/year. HIV staging is based on the Centers for Disease Control and Prevention’s surveillance case definition for AIDS. Donors HC1 and HC2 are healthy HIV-seronegative controls. ∗, not on HAART therapy at the time that blood was taken. The HAART treatment unresponsiveness of this cohort was similar to that described previously for patients with a history of extended treatment (34).

  • b Responses to all seven epitopes shown in Fig.3.